A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab.
Phase of Trial: Phase I/II
Latest Information Update: 19 Aug 2016
At a glance
- Drugs Buparlisib (Primary) ; Capecitabine; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 29 Oct 2015 Overall Response Rate added as the primary endpoint so the trial focus is also Therapeutic use, Capecitabine has been added in treatment as reported byb ClinicalTrials.gov.
- 29 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.